Q3 2025 Day One Biopharmaceuticals Inc Earnings Call Transcript
Key Points
- Day One Biopharmaceuticals Inc (DAWN) reported a 15% quarter-over-quarter increase in net product revenue, reaching $38.5 million, marking their strongest quarter in 2025.
- The company raised its full-year revenue guidance to a range of $145 to $150 million, reflecting confidence in the growth trajectory of Ogenda.
- Ogenda's adoption in the second line of treatment has grown by more than 60% over the past 12 months, indicating increasing physician confidence.
- The 2-year Firefly 1 data showed a manageable safety profile and durable clinical benefit, with growth velocity decreases being reversible post-treatment.
- Day One Biopharmaceuticals Inc (DAWN) ended the quarter with $451.6 million in cash and no debt, highlighting strong financial health and operational efficiency.
- Despite strong performance, the company is not yet guiding to profitability, indicating ongoing financial challenges.
- The commercial data on patient persistence is still maturing, making it difficult to provide detailed insights into long-term treatment adherence.
- There is uncertainty regarding the impact of the NCCN listing for Ogenda in adult gliomas on off-label use, as it is too early to determine its material effect.
- The company expects Q4 expenses to increase modestly due to planned commercial and clinical activities, which could impact short-term financial performance.
- The gross-to-net ratio was at the high end of the 12-15% range due to a CPIU penalty following a price increase, affecting short-term financial metrics.
Hello ladies and gentlemen and welcome to day one biopharmaceuticals 3rd quarter 2025 Financial and operating results conference call. At this time, all participants are in a listen-only mood. Later we will conduct a question-and-answer session. Please be advised that this conference call is being recorded. I would now like to turn the call over to your host, Joey Peron, senior Vice President of Finance and Investor relations.
Thank you. You may begin.
Thank you. Hello, everyone, and good afternoon. Welcome to day one's 3rd quarter financial and operating results conference call. Earlier today, we issued a press release that outlines the topics we plan to discuss today. You can access the press release in the slides to accompany this conference call on the investors and media section of our website at www.dayonebio.com. An audio webcast with the corresponding slides is also available on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
